BioNTech to buy FDA priority review voucher from Scholar Rock for $205 million
BNTX•BioNTech agreed to buy a US FDA Priority Review Voucher from Scholar Rock for $205 million in cash to support a future filing for a late-stage oncology asset.
1. Voucher purchase
BioNTech agreed to acquire a US FDA Priority Review Voucher from Scholar Rock for $205 million in cash. The voucher will support a future filing for a late-stage oncology asset and shorten the target FDA review timeline.
2. Closing conditions
The deal remains subject to customary conditions, including US antitrust clearance under the Hart-Scott-Rodino Act.
